Literature DB >> 7562573

Agonist and antagonist effects of dynorphin A-(1-13) in a thermal antinociception assay in rhesus monkeys.

E R Butelman1, C P France, J H Woods.   

Abstract

The agonist and antagonist effects of intravenously administered dynorphin A-(1-13) were characterized in the warm water (50 and 55 degrees C) tail withdrawal assay of antinociception in rhesus monkeys. The peptide dose-dependently elevated tail withdrawal latencies in 50 degrees C water, but was ineffective in 55 degrees C water. The antinociceptive effect of dynorphin was surmountably antagonized by quadazocine (0.1 mg/kg) and nor-binaltorphimine (3.2 mg/kg), but was not antagonized by clocinnamox (0.1 mg/kg); this pattern of antagonism is consistent with a kappa-opioid receptor mediated effect. Pretreatment with dynorphin A-(1-13) (0.032-3.2 mg/kg) antagonized the antinociceptive effects of U50,488 and U69,593 in 55 degrees C water, suggesting a low efficacy action of the peptide at the receptors activated by these kappa agonists. However, dynorphin A-(1-13) (3.2 mg/kg) did not antagonize other kappa agonists: bremazocine (0.018-0.056 mg/kg) and enadoline (0.0056-0.018 mg/kg). Taken together, these dynorphin A-(1-13) findings support the notion of functional kappa-opioid receptor subtypes, and it appears that dynorphin A-(1-13) has limited efficacy at one of these sites. Finally, dynorphin A-(1-13) (0.32 mg/kg) also antagonized the antinociceptive effects of the mu-agonist etonitazene (0.0018-0.01 mg/kg).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562573

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  4 in total

1.  Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.

Authors:  M C Ko; E R Butelman; J R Traynor; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

2.  Clocinnamox antagonism of opioid suppression of schedule-controlled responding in rhesus monkeys.

Authors:  E R Butelman; S S Negus; J W Lewis; J H Woods
Journal:  Psychopharmacology (Berl)       Date:  1996-02       Impact factor: 4.530

3.  Pleiotropic Effects of Kappa Opioid Receptor-Related Ligands in Non-human Primates.

Authors:  Mei-Chuan Ko; Stephen M Husbands
Journal:  Handb Exp Pharmacol       Date:  2020-12-04

Review 4.  Peptide kappa opioid receptor ligands: potential for drug development.

Authors:  Jane V Aldrich; Jay P McLaughlin
Journal:  AAPS J       Date:  2009-05-09       Impact factor: 4.009

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.